RedHill Biopharma (RDHL) Share-based Compensation (2012 - 2022)
RedHill Biopharma (RDHL) posted quarterly Share-based Compensation of $1.1 million for Q4 2022, down 39.36% year-over-year from $1.9 million in Q4 2021, and down 29.55% quarter-over-quarter from $1.6 million in Q3 2022.
RedHill Biopharma (RDHL) Share-based Compensation (2012 - 2022) Analysis & Trends
RedHill Biopharma (RDHL) has reported Share-based Compensation for 11 consecutive years, with $1.1 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Share-based Compensation fell 39.36% year-over-year to $1.1 million; the TTM figure through Dec 2022 stood at $5.7 million (down 44.43% YoY), while the FY2025 annual figure was $457000.0, down 31.28% from the prior year.
- Share-based Compensation slipped to $1.1 million in Q4 2022 per RDHL's latest filing, from $1.6 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.3 million in Q2 2021 and bottomed at $468000.0 in Q3 2018.
- Historically, Share-based Compensation has averaged $1.3 million across 5 years, with a median of $839000.0 in 2018.
- Annual changes were most pronounced in 2021 — Share-based Compensation jumped 746.55% — and 2022, when it sank 88.28%.
- RedHill Biopharma's Share-based Compensation stood at $671000.0 in 2018, then advanced by 11.62% to $749000.0 in 2019, then surged by 44.46% to $1.1 million in 2020, then jumped by 73.29% to $1.9 million in 2021, then plunged by 39.36% to $1.1 million in 2022.
- Business Quant data shows RDHL's Share-based Compensation at $1.1 million in Q4 2022, $1.6 million in Q3 2022, and $618000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.40 Bn | 43.44 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.69 Bn | 40.04 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 32.27 Bn | 30.60 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 21.99 Bn | 19.33 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.93 Bn | 18.04 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.59 Bn | 15.20 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.95 Bn | 11.42 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | RedHill Biopharma | 1.99 Bn | 1.99 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.14 Mn |
| Dec 31, 2022 | 1.14 Mn |
| Sep 30, 2022 | 1.61 Mn |
| Sep 30, 2022 | 1.61 Mn |
| Jun 30, 2022 | 618,000.00 |
| Jun 30, 2022 | 618,000.00 |
| Mar 31, 2022 | 2.31 Mn |
| Mar 31, 2022 | 2.31 Mn |
| Dec 31, 2021 | 1.88 Mn |
| Dec 31, 2021 | 1.88 Mn |
| Sep 30, 2021 | 2.19 Mn |
| Sep 30, 2021 | 2.19 Mn |
| Jun 30, 2021 | 5.27 Mn |
| Jun 30, 2021 | 5.27 Mn |
| Mar 31, 2021 | 872,000.00 |
| Mar 31, 2021 | 872,000.00 |
| Dec 31, 2020 | 1.08 Mn |
| Dec 31, 2020 | 1.08 Mn |
| Sep 30, 2020 | 1.70 Mn |
| Sep 30, 2020 | 1.70 Mn |